What Terns Pharmaceuticals, Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 0 | 12 |
| Total trades | 0 | 30 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 568,986 |
| Disposed | 0 | 716,572 |
| Net activity | +0 | −147,586 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Gengos Andrew | Chief Financial Officer | May 05 | Disposition to Issuer · D | −68,750 | $53.00 | −$3.64M | 0 |
| Gengos Andrew | Chief Financial Officer | May 05 | Tender Offer · U | −40,503 | $53.00 | −$2.15M | 0 |
| Burroughs Amy L. | Chief Executive Officer | May 05 | Disposition to Issuer · D | −150,000 | $53.00 | −$7.95M | 0 |
| Burroughs Amy L. | Chief Executive Officer | May 05 | Tender Offer · U | −8,319 | $53.00 | −$441K | 0 |
| Burroughs Amy L. | Chief Executive Officer | May 05 | Tender Offer · U | −146,614 | $53.00 | −$7.77M | 0 |
| Kuriakose Emil | Chief Medical Officer | May 05 | Disposition to Issuer · D | −81,953 | $53.00 | −$4.34M | 0 |
| Kuriakose Emil | Chief Medical Officer | May 05 | Tender Offer · U | −24,562 | $53.00 | −$1.3M | 0 |
| Kuriakose Emil | Chief Medical Officer | Apr 01 | Open-market sale · S | −942 | $52.75 | −$49.7K | 105,673 |
| Burroughs Amy L. | Chief Executive Officer | Mar 16 | Disclosed 10b5-1 sale · S | −2,770 | $47.30 | −$131K | 288,976 |
| Burroughs Amy L. | Chief Executive Officer | Mar 16 | Disclosed 10b5-1 sale · S | −11,813 | $46.57 | −$550K | 291,746 |
| Burroughs Amy L. | Chief Executive Officer | Mar 16 | Exercise / conversion · M | +14,583 | $4.64 | +$67.7K | 303,559 |
| Burroughs Amy L. | Chief Executive Officer | Feb 17 | Disclosed 10b5-1 sale · S | −4,083 | $39.80 | −$163K | 288,976 |
| Burroughs Amy L. | Chief Executive Officer | Feb 17 | Disclosed 10b5-1 sale · S | −8,159 | $39.22 | −$320K | 293,059 |
| Burroughs Amy L. | Chief Executive Officer | Feb 17 | Disclosed 10b5-1 sale · S | −2,341 | $38.07 | −$89.1K | 301,218 |
| Burroughs Amy L. | Chief Executive Officer | Feb 17 | Exercise / conversion · M | +14,583 | $4.64 | +$67.7K | 303,559 |
| Burroughs Amy L. | Chief Executive Officer | Jan 15 | Disclosed 10b5-1 sale · S | −7,521 | $37.53 | −$282K | 288,976 |
| Burroughs Amy L. | Chief Executive Officer | Jan 15 | Disclosed 10b5-1 sale · S | −61,228 | $37.02 | −$2.27M | 296,497 |
| Burroughs Amy L. | Chief Executive Officer | Jan 15 | Exercise / conversion · M | +14,583 | $4.64 | +$67.7K | 357,725 |
| Burroughs Amy L. | Chief Executive Officer | Jan 15 | Exercise / conversion · M | +27,083 | $4.64 | +$126K | 343,142 |
| Burroughs Amy L. | Chief Executive Officer | Jan 15 | Exercise / conversion · M | +27,083 | $4.64 | +$126K | 316,059 |
Loading...
